{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:22:37Z","timestamp":1768522957666,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002583","name":"Gyeongsang National University","doi-asserted-by":"publisher","award":["RS-2023-00235511"],"award-info":[{"award-number":["RS-2023-00235511"]}],"id":[{"id":"10.13039\/501100002583","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bbrc.2024.151001","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T15:05:30Z","timestamp":1731855930000},"page":"151001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Modeling of FAK-PROTAC candidates from GSK2256098 analogs for targeted protein degradation"],"prefix":"10.1016","volume":"740","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4468-3459","authenticated-orcid":false,"given":"Vikas","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6566-7496","authenticated-orcid":false,"given":"Shraddha","family":"Parate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-8401","authenticated-orcid":false,"given":"Hyeon-Su","family":"Ro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Sung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bbrc.2024.151001_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2024.151001_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110852","article-title":"Focal adhesion kinase (FAK): its structure, characteristics, and signaling in skeletal system","volume":"111","author":"Huang","year":"2023","journal-title":"Cell. Signal."},{"issue":"9","key":"10.1016\/j.bbrc.2024.151001_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2024.151001_bib4","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259089","article-title":"New insights into FAK structure and function in focal adhesions","volume":"135","author":"Le Coq","year":"2022","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbrc.2024.151001_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molcel.2007.11.031","article-title":"Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation","volume":"29","author":"Lim","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.bbrc.2024.151001_bib6","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.4161\/15384101.2014.949550","article-title":"A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells","volume":"13","author":"Zhang","year":"2014","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.bbrc.2024.151001_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"Mak","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2024.151001_bib8","volume":"vol. 32","author":"Patel","year":"2014"},{"key":"10.1016\/j.bbrc.2024.151001_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11523-018-00617-1","article-title":"Phase I study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies","volume":"14","author":"de Jonge","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.bbrc.2024.151001_bib10","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/acs.jmedchem.6b00487","article-title":"Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)","volume":"59","author":"Ott","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-023-02092-9","article-title":"FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest","volume":"40","author":"Pan","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bbrc.2024.151001_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26304","article-title":"Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program","volume":"64","author":"Kurmasheva","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bbrc.2024.151001_bib13","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.3390\/ijms23126381","article-title":"The development of FAK inhibitors: a five-year update","volume":"23","author":"Spallarossa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2024.151001_bib14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.drudis.2021.11.025","article-title":"Focal adhesion kinase inhibitors in the treatment of solid tumors: preclinical and clinical evidence","volume":"27","author":"Quispe","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2024.151001_bib15","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing kinase-independent functions of fak via PROTAC-mediated degradation","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.bbrc.2024.151001_bib16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2024.151001_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114373","article-title":"Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: design, synthesis, and biological study","volume":"237","author":"Sun","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib18","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1080\/14756366.2022.2100886","article-title":"Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs","volume":"37","author":"Qin","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13238-020-00732-8","article-title":"FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice","volume":"11","author":"Gao","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbrc.2024.151001_bib20","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/acs.jmedchem.8b01826","article-title":"Highly selective PTK2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions","volume":"62","author":"Popow","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Molecular Biomedicine"},{"issue":"7","key":"10.1016\/j.bbrc.2024.151001_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","article-title":"BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design","volume":"15","author":"Farnaby","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.bbrc.2024.151001_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbrc.2024.151001_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-46922-4","article-title":"Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL","volume":"15","author":"Nayak","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bbrc.2024.151001_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbrc.2024.151001_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2023.123504","article-title":"Targeting tachykinin peptides involved in viral infections through in silico approach: screening the unforeseen potency of serratiopeptidase","volume":"392","author":"Dhiman","year":"2023","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.bbrc.2024.151001_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2023.123039","article-title":"Structural insights into the lead identification of sub-type selective PDE4B inhibitors from plant bioactive molecule analogues","volume":"390","author":"Sharma","year":"2023","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.bbrc.2024.151001_bib28","article-title":"Multi-step synthesis of novel 2-methyl-3-carboxamide-4-quinolones and an enhanced sampling simulation method to identify potentiators for cystic fibrosis","volume":"33","author":"Sharma","year":"2023","journal-title":"Mater. Today Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib29","article-title":"Potential acridinedione derivatives for the development of a heterobifunctional PROTAC for targeted degradation of PCSK9 protein","volume":"38","author":"Bhardwaj","year":"2024","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.bbrc.2024.151001_bib30","doi-asserted-by":"crossref","first-page":"23327","DOI":"10.1002\/anie.202109237","article-title":"Discovery and characterisation of highly cooperative FAK-degrading PROTACs","volume":"60","author":"Law","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbrc.2024.151001_bib31","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.3390\/molecules26144250","article-title":"Drug discovery targeting focal adhesion kinase (FAK) as a promising cancer therapy","volume":"26","author":"Pang","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2024.151001_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2024.108789","article-title":"Computational insights into allosteric inhibition of focal adhesion kinase: a combined pharmacophore modeling and molecular dynamics approach","volume":"130","author":"Kumar","year":"2024","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bbrc.2024.151001_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbrc.2024.151001_bib34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/biomedicines9091197","article-title":"Identification of cdk7 inhibitors from natural sources using pharmacoinformatics and molecular dynamics simulations","volume":"9","author":"Kumar","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbrc.2024.151001_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2020.104186","article-title":"A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment","volume":"130","author":"Kumar","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bbrc.2024.151001_bib36","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jcc.21726","article-title":"Combination of the CHARMM27 force field with united-atom lipid force fields","volume":"32","author":"Sapay","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib38","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/jcc.21816","article-title":"SwissParam: a fast force field generation tool for small organic molecules","volume":"32","author":"Zoete","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib39","doi-asserted-by":"crossref","first-page":"10096","DOI":"10.1063\/1.1808117","article-title":"A modified TIP3P water potential for simulation with Ewald summation","volume":"121","author":"Price","year":"2004","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bbrc.2024.151001_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrc.2024.151001_bib41","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N\u22c5log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bbrc.2024.151001_bib42","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bbrc.2024.151001_bib43","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/minf.201100135","article-title":"Free energy calculations by the molecular Mechanics Poisson\u2212Boltzmann Surface Area method","volume":"31","author":"Homeyer","year":"2012","journal-title":"Mol Inform"},{"key":"10.1016\/j.bbrc.2024.151001_bib44","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"G-mmpbsa -A GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.bbrc.2024.151001_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-36956-5","article-title":"Structural mechanism of a drug-binding process involving a large conformational change of the protein target","volume":"14","author":"Ayaz","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbrc.2024.151001_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2024.151001_bib47","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/bioinformatics\/btl461","article-title":"Bio3d: an R package for the comparative analysis of protein structures","volume":"22","author":"Grant","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bbrc.2024.151001_bib48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/cbdd.13653","article-title":"Impact of lymphoma-linked Asn11Tyr point mutation on the interaction between Bcl-2 and a BH3 mimetic: insights from molecular dynamics simulation","volume":"95","author":"Singh","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bbrc.2024.151001_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/biom13020217","article-title":"Identification of activated cdc42-associated kinase inhibitors as potential anticancer agents using pharmacoinformatic approaches","volume":"13","author":"Kumar","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2024.151001_bib50","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-07-5155","article-title":"Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271","volume":"68","author":"Roberts","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2024.151001_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.bbrc.2024.151001_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2016.05.007","article-title":"BDDCS, the Rule of 5 and drugability","volume":"101","author":"Benet","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2024.151001_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.909111","article-title":"3D-QSAR-Based pharmacophore modeling, virtual screening, and molecular dynamics simulations for the identification of spleen tyrosine kinase inhibitors","volume":"12","author":"Kumar","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bbrc.2024.151001_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.132476","article-title":"Structural-based virtual screening and identification of novel potent antimicrobial compounds against YsxC of Staphylococcus aureus","volume":"1255","author":"Kumari","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bbrc.2024.151001_bib55","doi-asserted-by":"crossref","first-page":"9833","DOI":"10.1080\/07391102.2021.1936179","article-title":"Identification of potential inhibitors for LLM of Staphylococcus aureus: structure-based pharmacophore modeling, molecular dynamics, and binding free energy studies","volume":"40","author":"Kumari","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2024.151001_bib56","doi-asserted-by":"crossref","first-page":"32442","DOI":"10.1021\/acsomega.2c03951","article-title":"Molecular docking, molecular dynamics simulations, and free energy calculation insights into the binding mechanism between VS-4718 and focal adhesion kinase","volume":"7","author":"Shi","year":"2022","journal-title":"ACS Omega"},{"issue":"5","key":"10.1016\/j.bbrc.2024.151001_bib57","first-page":"273","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Open Exploration"},{"key":"10.1016\/j.bbrc.2024.151001_bib58","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bbrc.2024.151001_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200615","article-title":"Systematic potency and property assessment of VHL ligands and implications on PROTAC design","volume":"18","author":"Krieger","year":"2023","journal-title":"ChemMedChem"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24015377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24015377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T13:33:40Z","timestamp":1732973620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X24015377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":59,"alternative-id":["S0006291X24015377"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.151001","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling of FAK-PROTAC candidates from GSK2256098 analogs for targeted protein degradation","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.151001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151001"}}